Search Results

You are looking at 31 - 40 of 595 items for :

  • "surveillance" x
Clear All
Full access

Al B. Benson III, Alan P. Venook, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Axel Grothey, Howard S. Hochster, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Lucille A. Leong, Edward Lin, Wells A. Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory and Deborah Freedman-Cass

that strict surveillance in these patients, with resection of recurrences when possible, resulted in a 5-year local recurrence-free survival of 69%, which was converted to 94% after resections were performed. 27 Despite these impressive results, the

Full access

Thomas B. Nealis, Kay Washington and Rajesh N. Keswani

differentiation is important but can be difficult to ascertain via EUS. 25 Because of this difficulty, EMR of visible lesions is the current standard, 26 and allows both accurate staging and possible curative treatment at the same session. Surveillance

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Rashmi Kumar and Dorothy A. Shead

manuscript discusses the workup, primary treatment, risk reduction strategies, and surveillance for DCIS. Workup The recommended workup and staging of DCIS includes a history and physical examination; bilateral diagnostic mammography, pathology review

Full access

Arvind Bambhroliya, Mariana Chavez-MacGregor and Abenaa M. Brewster

-risk consultations (85%) were conducted by primary care providers (PCPs). The study that reported the highest uptake rate of 54.4% evaluated acceptance of risk reduction medications at a breast surveillance clinic that provided comprehensive risk assessment and

Full access

Andrew D. Zelenetz, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nishitha Reddy, Lubomir Sokol, Lode Swinnen, Christina Tsien, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Maoko Naganuma and Mary A. Dwyer

) for NHLs are developed and updated as a result of annual meetings convened by a multidisciplinary panel of NHL experts, with the goal of providing recommendations on the standard practices for diagnostic workup, treatment, and surveillance strategies

Full access

Brandon R. Mason, James A. Eastham, Brian J. Davis, Lance A. Mynderse, Thomas J. Pugh, Richard J. Lee and Joseph E. Ippolito

PSA level increases and systematic TRUS biopsy results remain negative. 15 Role of mpMRI in Active Surveillance Active surveillance involves the active monitoring of men with seemingly indolent PCa with the goal of initiating therapy if tumor

Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory and Deborah A. Freedman-Cass

cancer and <1 cm for perianal cancer) received local radiation, and all patients underwent surveillance. After a median follow-up of 45 months, no differences were seen in 5-year OS (100% for the entire cohort) or 5-year cancer recurrence-free survival

Full access

James L. Mohler

Amling provides the basis for updating the best available nomograms in the 2010 version of the NCCN Guidelines to help provide more individualized recommendations. This need for individualization includes both choice of treatment (active surveillance vs

Full access

Patrick M. Lynch

performance of genetic counselor–driven germline mutation testing, in patients with hereditary nonpolyposis colorectal cancer (HNPCC)–related tumors, also known as Lynch syndrome. Suitably aggressive colorectal neoplasm surveillance is shown to be critical

Full access

Carlos H. Barcenas, Maryam N. Shafaee, Arup K. Sinha, Akshara Raghavendra, Babita Saigal, Rashmi K. Murthy, Ashley H. Woodson and Banu Arun

initially published and widely disseminated, and therefore may not have been offered a referral for genetic counseling at initial diagnosis or at subsequent surveillance visits. 11 In our practice within a breast cancer survivorship clinic at The